Novartis reports long-term results of ofatumumab for multiple sclerosis (MS) from an ongoing label extension of the ALTHIOS study

Data from study shows mean immunoglobulin G (IgG) and immunoglobulin M (IgM) were preserved in adults with relapsing multiple sclerosis (MS) over 3.5 years receiving this B-cell targeting therapy.

SPS commentary:

NICE recommends ofatumumab as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features. This is only if the company provides ofatumumab according to the commercial arrangement.

PharmaTimes